Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Published

Journal Article

BACKGROUND: Recommendations for management of cancer-related venous thromboembolism (VTE) in patients already receiving anticoagulant therapy are based on low-quality evidence. This international registry sought to provide more information on outcomes after a breakthrough VTE in relation to anticoagulation strategies. METHODS: Patients with cancer and VTE despite anticoagulant therapy were reported to the registry. Data on treatments, VTE events, major bleeding, residual thrombosis symptoms and death were collected for the following 3 months. Breakthrough VTE and subsequent recurrences were objectively verified. Outcomes with different treatment strategies were compared with Cox proportional hazards regression. RESULTS: We registered 212 patients with breakthrough VTE. Of those, 59% had adenocarcinoma and 73% had known metastases. At the time of the breakthrough event, 70% were on low-molecular-weight heparin (LMWH) and 27% on a vitamin K antagonist (VKA); 70% had a therapeutic or supratherapeutic dose. After breakthrough the regimen was: unchanged therapeutic dose in 33%, dose increased in 31%, switched to another drug in 24%; and other management in 11%. During the following 3 months 11% had another VTE, 8% had major bleeding and 27% died. Of the survivors, 74% had residual thrombosis symptoms. Additional VTE recurrence was less common with LMWH than with a VKA (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.11-0.70) but similar with unchanged or increased anticoagulant intensity (HR, 1.09; 95% CI, 0.45-2.63). The bleeding rate did not increase significantly with dose escalation. CONCLUSION: Morbidity and mortality are high after recurrence of cancer-related VTE despite anticoagulation. Further treatment appears to be more effective with LMWH than with a VKA.

Full Text

Duke Authors

Cited Authors

  • Schulman, S; Zondag, M; Linkins, L; Pasca, S; Cheung, YW; de Sancho, M; Gallus, A; Lecumberri, R; Molnar, S; Ageno, W; Le Gal, G; Falanga, A; Hulegårdh, E; Ranta, S; Kamphuisen, P; Debourdeau, P; Rigamonti, V; Ortel, TL; Lee, A

Published Date

  • June 2015

Published In

Volume / Issue

  • 13 / 6

Start / End Page

  • 1010 - 1018

PubMed ID

  • 25851122

Pubmed Central ID

  • 25851122

Electronic International Standard Serial Number (EISSN)

  • 1538-7836

Digital Object Identifier (DOI)

  • 10.1111/jth.12955

Language

  • eng

Conference Location

  • England